- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | MAIA Biotechnology, Inc.: MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer | 165 | GlobeNewswire (Europe) | Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc.... ► Artikel lesen | |
| 06.10. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal | 248 | GlobeNewswire (Europe) | THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| 22.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer | 318 | GlobeNewswire (Europe) | Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed... ► Artikel lesen | |
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 16.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial | 447 | GlobeNewswire (Europe) | Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies U.S. expansion is funded by a $2.3 million... ► Artikel lesen | |
| 15.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO | 1 | GlobeNewswire (USA) | ||
| 10.09. | MAIA Biotechnology, Inc.: MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 | 2 | GlobeNewswire (USA) | ||
| 10.08. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.07. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial | 425 | GlobeNewswire (Europe) | 90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated... ► Artikel lesen | |
| 25.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer | 354 | GlobeNewswire (Europe) | Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage... ► Artikel lesen | |
| 18.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University | 343 | GlobeNewswire (Europe) | Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE... ► Artikel lesen | |
| 10.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial | 384 | GlobeNewswire (Europe) | Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected... ► Artikel lesen | |
| 04.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial | 353 | GlobeNewswire (Europe) | MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE... ► Artikel lesen | |
| 03.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion | 359 | GlobeNewswire (Europe) | Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing... ► Artikel lesen | |
| 02.06. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Open Market Purchases by CEO and Director | 3 | GlobeNewswire (USA) | ||
| 22.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.05. | MAIA Biotechnology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 354 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 280 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 141,38 | +2,69 % | Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers | ||
| ABBVIE | 255,40 | +0,47 % | Community Rückblick: wO-User zum Kurssturz bei Newron Pharma: "Der Wirkstoff ist - Stand jetzt - tot" | © Foto: Newron Pharmaceuticals SpAFDA-Schock bei Newron Pharma: Nach dem Kurssturz entbrennt im wO-Forum eine hitzige Debatte über Todesfälle, Managementkommunikation und die Zukunft des Hoffnungsträgers... ► Artikel lesen | |
| ABBOTT LABORATORIES | 93,42 | +1,19 % | Abbott Laboratories (ABT): Ausbruch über die 101-Dollar-Marke läuft! | Bodenbildung abgeschlossen - Rebound optimal handeln! Rückblick Die Aktie von Abbott erlebte im Sommer eine starke Rallye von Niveaus um 82.50 USD bis auf ein Hoch von rund 117 USD Mitte August. Daraufhin... ► Artikel lesen | |
| EYEPOINT | 2,740 | +1,48 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SCHOTT PHARMA | 24,550 | +0,20 % | DEUTSCHE BANK RESEARCH stuft Schott Pharma auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Schott Pharma von "Buy" auf "Hold" abgestuft, das Kursziel aber von 23 auf 25 Euro angehoben. Der Pharmazulieferer habe klare Fortschritte gemacht... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 76,64 | -1,11 % | UBS reiterates Edwards Lifesciences stock rating on endpoint expectations | ||
| ASSEMBLY BIOSCIENCES | 18,240 | -0,87 % | Assembly Biosciences: Was die neuen Studiendaten verraten | ||
| PENTIXAPHARM | 1,825 | -1,08 % | EQS-AFR: Pentixapharm Holding AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: Pentixapharm Holding AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Pentixapharm Holding AG: Vorabbekanntmachung... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 33,480 | +1,30 % | Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology | ||
| FILANA THERAPEUTICS | 0,650 | -1,22 % | Filana Therapeutics, Inc.: Filana Therapeutics to Participate in the 2026 Maxim Growth Summit | ||
| AXSOME THERAPEUTICS | 149,70 | +2,99 % | RBC Capital reiterates Axsome Therapeutics stock rating at Outperform | ||
| MEDPACE | 562,20 | +1,66 % | Morning Market Movers: 707 Cayman, Zhongchao, NVE Corporation, Medpace See Big Swings | BEIJING (dpa-AFX) - At 8:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZEALAND PHARMA | 30,860 | +1,95 % | Zealand Pharma pens $1.2bn AI obesity drug discovery pact with Generate | ||
| UNITED THERAPEUTICS | 492,30 | +1,63 % | Liquidia Settles All Litigation With United Therapeutics; Shares Rise | WASHINGTON (dpa-AFX) - Liquidia Corp. (LQDA), a biopharmaceutical company, announced that it has entered into a global settlement agreement with United Therapeutics Corp. (UTHR) resolving all... ► Artikel lesen | |
| UCB | 206,20 | +1,93 % | UCB Dedicates Future Site of US Biologics Manufacturing Campus in Georgia |
MAIA BIOTECHNOLOGY INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,44 % bei einem Aktienkurs von 1,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.